Browsing Tag
Nasdaq Stockholm
10 posts
EQT exits Enity Holding as Nordic mortgage lender faces its next market test
EQT is out, Enity is public and the discount was visible. The next test is whether Nordic mortgage growth can outrun investor caution.
Autoliv (NYSE: ALV) stock in focus as Türkiye closure adds $142m restructuring charge
Autoliv is cutting Türkiye capacity as auto demand flattens. The real test is whether a $142M charge can protect future margins.
Ericsson posts 6% organic growth in Q1 2026 as currency headwinds mask gains across four global markets
Ericsson posts 6% organic Q1 2026 growth and nearly doubles free cash flow, but SEK 3.8B restructuring charges and legal risks complicate the recovery story. Read more.
Maha Capital moves fast on PetroUrdaneta as OFAC authorises US-entity transactions with PdVSA under GL 52
Maha Capital exercises a EUR 4.6m call option for PetroUrdaneta the same day OFAC publishes GL 52, opening Venezuela's oil sector to US entities. Read the analysis.
Yubico expands C-suite with cybersecurity veterans — can this fuel the next phase of phishing-resistant security?
Yubico expands leadership team with new CFO, CPTO, and SVP to accelerate growth in global authentication. Learn what this means for investors.
Imlifidase clears pivotal US Phase 3 trial with strong kidney transplant results as Hansa Biopharma eyes FDA filing
Hansa Biopharma’s Imlifidase meets its Phase 3 trial endpoint in US kidney transplantation, setting up FDA filing and reshaping biotech investor sentiment.
Verisure’s €3.1bn IPO on Nasdaq Stockholm: Is Europe’s biggest security firm worth buying?
Verisure’s €3.1B Nasdaq Stockholm IPO signals a comeback to public markets. Find out why it matters for investors, Sweden, and Europe’s IPO revival.
Hexagon AB appoints Anders Svensson as President and CEO as it eyes autonomy, robotics, and AI-led growth
Anders Svensson takes over as Hexagon AB CEO, steering autonomy, AI, and spin-off plans. Find out what this means for growth and investor sentiment.
BioArctic advances exidavnemab phase 2a cohorts after safety review
BioArctic expands its Phase 2a trial for exidavnemab after a successful safety review. Read how this impacts Parkinson’s and MSA drug development today.
Aristocrat Leisure to refocus on core gaming with Plarium Global sale to Modern Times Group
Aristocrat Leisure Limited has announced a pivotal decision to sell its mobile gaming subsidiary, Plarium Global, to Modern…